These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26219898)

  • 1. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.
    Lin H; Jiang X; Zhu H; Jiang W; Dong X; Qiao H; Sun X; Jiang H
    Tumour Biol; 2016 Jan; 37(1):381-91. PubMed ID: 26219898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
    Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
    Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Wu PK; Park JI
    Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
    Miles D; Jumbe NL; Lacy S; Nguyen L
    Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Lloyd RV; Park JI
    Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib: a review of its use in patients with medullary thyroid cancer.
    Hoy SM
    Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1α response after traumatic brain injury in mice.
    Schaible EV; Windschügl J; Bobkiewicz W; Kaburov Y; Dangel L; Krämer T; Huang C; Sebastiani A; Luh C; Werner C; Engelhard K; Thal SC; Schäfer MK
    J Neurochem; 2014 Jun; 129(6):940-54. PubMed ID: 24606183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
    Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
    J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer agent 2-methoxyestradiol improves survival in septic mice by reducing the production of cytokines and nitric oxide.
    Yeh CH; Chou W; Chu CC; So EC; Chang HC; Wang JJ; Hsing CH
    Shock; 2011 Nov; 36(5):510-6. PubMed ID: 21841536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cabozantinib: Mechanism of action, efficacy and indications].
    Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
    Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib for the treatment of advanced medullary thyroid cancer.
    Nagilla M; Brown RL; Cohen EE
    Adv Ther; 2012 Nov; 29(11):925-34. PubMed ID: 23104465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.
    Starenki D; Singh NK; Jensen DR; Peterson FC; Park JI
    Cancer Lett; 2013 Oct; 339(1):144-51. PubMed ID: 23856028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-methoxyestradiol reduces cerebral vasospasm after 48 hours of experimental subarachnoid hemorrhage in rats.
    Yan J; Chen C; Lei J; Yang L; Wang K; Liu J; Zhou C
    Exp Neurol; 2006 Dec; 202(2):348-56. PubMed ID: 16904108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
    Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
    PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.